Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: A mono-institutional phase II study

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 1, 2008, Pages 149-155

  Ferraresi, Virginia ^a   Ciccarese, Mariangela ^a   Cercato, Maria Cecilia ^a   Nuzzo, Carmen ^a   Zeuli, Massimo ^a   Di Filippo, Franco ^a   Giannarelli, Diana ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antitumor activity; Chemotherapy; Gemcitabine; Soft tissue sarcoma; Toxicity

Indexed keywords

ANTIEMETIC AGENT; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER CONTROL; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENDOMETRIUM SARCOMA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LEIOMYOSARCOMA; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEURILEMOMA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 53149109402     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0723-9     Document Type: Article

References (35)

1. A Jemal R Siegel E Ward 2006 Cancer statistics, 2006 CA Cancer J Clin 56 106 130
2. AI Spira DS Ettinger 2002 The use of chemotherapy in soft-tissue sarcomas Oncologist 7 348 359
3. W Plunkett P Huang YZ Xu V Heinemann R Grunewald V Gandhi 1995 Gemcitabine: metabolism, mechanism of action, and self-potentiation Semin Oncol 22 3 10
4. O Merimsky I Meller G Flusser 2000 Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study Cancer Chemother Pharmacol 45 177 181
5. E Späth-Schwalbe I Genvresse A Koschuth A Dietzmann R Grunewald K Possinger 2000 Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas Anticancer Drugs 11 325 329
6. SR Patel V Gandhi J Jenkins 2001 Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation J Clin Oncol 19 3483 3489
7. BL Samuels L Barbour D Schiller 2001 Phase I study of low dose continuous infusion gemcitabine in sarcoma patients [abstract] Proc Am Soc Clin Oncol 20 2935
8. S Bauer J Hartung T Gauler 2002 Gemcitabine-containing chemotherapy in the treatment of patients with advanced soft tissue sarcoma Tumordiagn Ther 23 219 224
9. KY Look A Sandler JA Blessing III JA Lucci PG Rose 2004 Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study Gynecol Oncol 92 644 647
10. JL Abbruzzese R Grunewald EA Weeks 1991 A phase I clinical, plasma and cellular pharmacology study of gemcitabine J Clin Oncol 9 491 498
11. CF Pollera A Ceribelli M Crecco F Calabresi 1994 Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study Invest New Drugs 12 111 119
12. R Grunewald H Kantarjian MJ Keating J Abbruzzese P Tarassoff W Plunkett 1990 Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia Cancer Res 50 6823 6826
13. National Cancer Institute. CTEP. Common Toxicity Criteria, v.2.0. http://ctep.cancer.gov/reporting/ctc.html (accessed 6 September 2007)
14. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216
15. TR Fleming 1982 One-sample multiple testing procedure for phase II clinical trials Biometrics 38 143 151
16. N Touroutoglou D Gravel MN Rabel W Plunkett JL Abbruzzese 1998 Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors Ann Oncol 9 1003 1008
17. R Brand M Capadano M Tempero 1997 A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors Invest New Drugs 15 331 341
18. A Amodio S Carpano C Manfredi 1999 Gemcitabine in advanced soft tissue sarcoma: a phase II study Clin Ter 150 17 20
19. U Gautam J Hurley OE Silva PW Benedetto C Robles 2002 Gemcitabine: an active chemotherapeutic agent for angiosarcoma [abstract] Proc Am Soc Clin Oncol 21 2931
20. S Okuno J Edmonson M Mahoney JC Buckner S Frytak E Galanis 2002 Phase II trial of gemcitabine in advanced sarcomas Cancer 94 3225 3229
21. L Švancárová JY Blay IR Judson 2002 Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 38 556 559
22. S Okuno LM Ryan JH Edmonson DA Priebat RH Blum 2003 Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). A trial of the Eastern Cooperative Oncology Group Cancer 97 1969 1973
23. JT Hartmann K Oechsle J Huober 2006 An open label, non comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma Invest New Drugs 24 249 253
24. G Von Burton C Rankin MM Zalupski GM Mills EC Borden A Karen 2006 Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma Am J Clin Oncol 29 59 61
25. ML Hensley R Maki E Venkatraman 2002 Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial J Clin Oncol 20 2824 2831
26. RG Maki JK Wathen SR Patel 2007 Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research through collaboration study 002 (corrected) J Clin Oncol 25 2755 2763
27. JM Buesa R Losa A Fernández 2004 Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation Cancer 101 2261 2269
28. R Losa J Fra A López-Pousa 2007 Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas Cancer Chemother Pharmacol 59 251 259
29. A López-Pousa R Losa J Martin 2006 Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study Br J Cancer 94 1797 1802
30. P Dileo JA Morgan D Zahrieh 2007 Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial Cancer 109 1863 1869
31. N Xu P Shen XC Zhang 2007 Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer Cancer Chemother Pharmacol 59 1 7
32. JR Pereira L Fein A Del Giglio 2007 Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer Lung Cancer 58 80 87
33. H Kim JH Park SJ Shin 2008 Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study Chemotherapy 54 54 62
34. W Sun MR Hewitt MR Theobald D Hershock DG Haller 2007 A phase I study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer Cancer 110 2768 2774
35. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ; Cancer, Leukemia Group B (2008) A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int 101:20-25